RxDoctor Payments Data

Matthew Knapke, MD

Family Medicine · Westerville, OHNPI 1083063796

Payments from drug & device makers

$4,618in general payments, 2019–2025

Across 256 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$702
  • AstraZeneca$534
  • Novo Nordisk$503
  • GSK$400
  • Lilly USA, LLC$331
  • Pfizer$307
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$4,618100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,618 in reported general payments places this provider in the 85th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$163,969
Medicare patients
311
Services billed
6,561

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin86$108,094
OzempicSemaglutide78$95,475
EliquisApixaban89$93,071
MounjaroTirzepatide64$70,488
FarxigaDapagliflozin Propanediol34$46,216
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$38,784
RybelsusSemaglutide24$31,482
TrulicityDulaglutide28$29,923
XareltoRivaroxaban15$23,425
Spiriva RespimatTiotropium Bromide13$6,732
SymbicortBudesonide/Formoterol Fumarate24$5,385
Rosuvastatin Calcium364$5,150
Tresiba Flextouch U-100Insulin Degludec15$4,886
Atorvastatin Calcium429$4,311
Lantus SolostarInsulin Glargine,hum.Rec.Anlog51$3,921

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$503$126,958102 claims
Boehringer IngelheimJardiance, Spiriva Respimat$146$114,82599 claims
Lilly USA, LLCMounjaro, Trulicity$331$100,41192 claims
PfizerEliquis$307$93,07189 claims
AstraZenecaFarxiga, Symbicort$534$51,60258 claims
GSKTrelegy Ellipta$400$38,78457 claims
Johnson & JohnsonXarelto$43$23,42515 claims
AbbVieSynthroid$702$2,10952 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Westerville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →